FrancophonIA/ELRC3.0 huggingface dataset:
English: Liraglutide exposure was reduced in patients with renal impairment compared to individuals with normal renal function.
Slovenian: Pri bolnikih z okvaro ledvic je bila izpostavljenost liraglutidu manjša kot pri osebah z normalnim delovanjem ledvic.
English: Substances added to Xultophy may cause degradation of the active substances.
Slovenian: Dodajanje drugih snovi zdravilu Xultophy lahko povzroči razgradnjo učinkovin v zdravilu.
English: The medicinal product should be discarded 21 days after first opening.
Slovenian: 21 dni po prvem odprtju je zdravilo treba zavreči.
English: FAS: full analysis set
Slovenian: PAP: popolna analiza podatkov IZ: interval zaupanja
English: A drop of solution should appear at the needle tip.
Slovenian: Na konici igle se mora pojaviti kapljica raztopine.
English: Further important information • Always keep an extra pen and new needles, in case of loss or damage.
Slovenian: • Vedno imejte pri sebi rezervni injekcijski peresnik in nove igle, za primer, če injekcijski peresnik ali igle izgubite ali se poškodujejo.
English: • low blood sugar (hypoglycaemia) - if your blood sugar is low, follow the advice in section 4 ‘Low blood sugar (hypoglycaemia)'.
Slovenian: • na prenizek krvni sladkor (hipoglikemija) - če je koncentracija krvnega sladkorja majhna, upoštevajte nasvete v poglavju 4 “Prenizek krvni sladkor (hipoglikemija)”,
English: C Count slowly:
Slovenian: C štejte počasi:
English: Limited data are available with regard to overdose of Xultophy.
Slovenian: Podatki o prevelikem odmerjanju zdravila Xultophy so omejeni.
English: Having low or high blood sugar can affect your ability to drive or use any tools or machines.
Slovenian: Vpliv na sposobnost upravljanja vozil in strojev Previsok ali prenizek krvni sladkor lahko vplivata na sposobnost upravljanja vozil in strojev.
English: Very few patients developed insulin degludec specific antibodies, antibodies cross-reacting to human insulin or anti-liraglutide antibodies following treatment with Xultophy.
Slovenian: Med zdravljenjem z zdravilom Xultophy so se specifična protitelesa proti insulinu degludek, protitelesa, ki navzkrižno reagirajo s humanim insulinom ali protitelesa proti liraglutidu razvila pri zelo majhnem številu bolnikov.
English: The non-clinical development programme for insulin degludec/liraglutide included pivotal combination toxicity studies of up to 90 days duration in a single relevant species (Wistar rats) to support the clinical development programme.
Slovenian: V podporo kliničnemu razvojnemu programu so v okviru nekliničnega razvojnega programa insulina degludek/liraglutida izvedli ključne študije toksičnosti kombinacije pri eni pomembni vrsti (Wistar podgane).
English: Lipodystrophy (including lipohypertrophy, lipoatrophy) may occur at the injection site.
Slovenian: Na mestu injiciranja zdravila se lahko pojavi lipodistrofija (vključno z lipohipertrofijo in lipoatrofijo).
English: Table 3 Results at 26-weeks - Add on to oral glucose-lowering medicinal products
Slovenian: Preglednica 3: Rezultati po 26 tednih - dodatek k zdravljenju s peroralnimi antidiabetiki
English: • The active substances are insulin degludec and liraglutide.
Slovenian: • Učinkovini sta insulin degludek in liraglutid.
English: Compared to baseline, Xultophy resulted in an unchanged mean body weight compared to a mean weight increase of 2.0 kg for patients treated with insulin glargine (estimated treatment difference -1.92 kg [95% CI: -2.64; -1.19]).
Slovenian: primerjavi z izhodiščem se pri uporabi zdravila Xultophy povprečna telesna masa bolnikov ni spremenila, pri bolnikih, ki so se zdravili z insulinom glargin, pa je prišlo do povprečnega povečanja telesne mase za 2,0 kg (ocenjena razlika zdravljenja -1,92 kg [95 % IZ: -2,64; -1,19]).
English: If you use more Xultophy than you should, your blood sugar may get low (hypoglycaemia) or you may feel or be sick (nausea or vomiting).
Slovenian: Če ste uporabili večji odmerek zdravila Xultophy, kot bi smeli Če ste uporabili večji odmerek zdravila Xultophy, kot bi smeli, se koncentracija krvnega sladkorja lahko prekomerno zmanjša (hipoglikemija) ali se pojavi siljenje na bruhanje ali bruhanje.
English: No dose adjustment of lisinopril is required based on these results.
Slovenian: Na osnovi teh rezultatov odmerka lizinoprila ni treba prilagajati.
English: Xultophy is a combination product consisting of insulin degludec and liraglutide having complementary mechanisms of action to improve glycaemic control.
Slovenian: Zdravilo Xultophy je kombinacija dveh učinkovin, insulina degludek in liraglutida, ki delujeta komplementarno na izboljšanje urejenosti glikemije.
English: The maximum allowed dose in the trial was 50 dose steps for Xultophy whereas there was no maximum dose for insulin glargine.
Slovenian: Največji dovoljeni odmerek zdravila Xultophy je bil 50 odmernih korakov, največji odmerek insulina glargin pa ni bil določen.
English: • high blood sugar (hyperglycaemia) - if your blood sugar is high, follow the advice in section 4 ‘High blood sugar (hyperglycaemia)'.
Slovenian: • na previsok krvni sladkor (hiperglikemija) - če je koncentracija krvnega sladkorja velika, upoštevajte nasvete v poglavju 4 “Previsok krvni sladkor (hiperglikemija)”,
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING MULTIPACK LABEL
Slovenian: PODATKI NA ZUNANJI OVOJNINI NALEPKA NA PAKIRANJU PO VEČ ENOT
English: Insulin degludec
Slovenian: Insulin degludek
English: Liraglutide did not change the overall exposure of atorvastatin to a clinical relevant degree following single dose administration of atorvastatin 40 mg.
Slovenian: Liraglutid po enkratnem 40-mg odmerku atorvastatina ni spremenil celokupne izpostavljenosti atorvastatinu v klinično pomembnem obsegu.
English: Rates of confirmed hypoglycaemia were lower with Xultophy than with insulin degludec irrespective of the glycaemic control, see Figure 1.
Slovenian: Delež potrjene hipoglikemije je bil pri zdravilu Xultophy manjši kot pri insulinu degludek, ne glede na urejenost glikemije.
English: The overall exposure of liraglutide was equivalent following administration of Xultophy versus liraglutide alone while Cmax was lower by 23%.
Slovenian: Pri uporabi zdravila Xultophy je bila celokupna izpostavljenost liraglutidu enaka kot pri uporabi liraglutida samega, največja koncentracija (Cmax) pa je bila manjša za 23 %.
English: Always use a new needle for each injection.
Slovenian: Za vsako injiciranje vedno uporabite novo injekcijsko iglo.
English: Liraglutide exposure was lowered by 33%, 14%, 27% and 26%, in patients with mild (creatinine clearance, CrCl 50-80 mL/min), moderate (CrCl 30-50 mL/min), and severe (CrCl <30 mL/min) renal impairment and in end-stage renal disease requiring dialysis, respectively.
Slovenian: Pri bolnikih z blago okvaro ledvic (kreatininski očistek 50-80 ml/min) je bila izpostavljenost liraglutidu manjša za 33 %, pri bolnikih z zmerno okvaro ledvic (kreatininski očistek 30-50 ml/min) za 14 %, pri bolnikih s hudo okvaro ledvic (kreatininski očistek < 30 ml/min) za 27 %,
English: Non-clinical data reveal no safety concern for humans based on studies of safety pharmacology, repeated dose toxicity, carcinogenic potential, and toxicity to reproduction.
Slovenian: Neklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, kancerogenega potenciala in vpliva na sposobnost razmnoževanja ne kažejo posebnega tveganja za človeka.
English: • Never share your needles with other people.
Slovenian: • Injekcijskih igel si ne smete deliti z drugimi.
English: The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia defined as an episode requiring assistance of another person was 0.01 (2 patients out of 825) for Xultophy, 0.01 (2 patients out of 412) for insulin degludec and 0.00 (0 patients out of 412) for liraglutide.
Slovenian: Delež hude hipoglikemije, opredeljene kot dogodek, pri katerem je potrebna pomoč druge osebe, na bolnikov-let izpostavljenosti (odstotek bolnikov), je bil pri zdravilu Xultophy 0,01 (2 od 825 bolnikov), pri insulinu degludek 0,01 (2 od 412 bolnikov), pri liraglutidu pa
English: Tell your doctor if you are taking warfarin or other blood thinners as you might need to have blood tests more often to measure how thick your blood is (called ‘International Normalised Ratio' or INR test).
Slovenian: V tem primeru bodo morda potrebne pogostejše krvne preiskave za določanje hitrosti strjevanja krvi (imenovane test mednarodnega normaliziranega razmerja ali INR).
English: In this context, relevant precautions as reflected in the SmPC should be emphasised.
Slovenian: V skladu s tem je treba poudariti preventivne ukrepe, ki so navedeni v povzetku glavnih značilnosti zdravila;
English: The pre-filled pen is for use by one person only.
Slovenian: Napolnjen injekcijski peresnik je namenjen za uporabo pri enem samem bolniku.
English: When transferring from a GLP-1 receptor agonist, the recommended starting dose of Xultophy is 16 dose steps (16 units insulin degludec and 0.6 mg liraglutide) (see section 5.1).
Slovenian: Priporočeni začetni odmerek zdravila Xultophy pri prehodu z zdravljenja z agonistom receptorjev GLP-1 je 16 odmernih korakov (16 enot insulina degludek in 0,6 mg liraglutida) (glejte poglavje 5.1).
English: In a second trial, the transfer from basal insulin to Xultophy or insulin degludec was investigated in a 26-week randomised, double-blind trial in patients inadequately controlled on basal insulin (20-40 units) and metformin alone or in combination with sulfonylurea/glinides.
Slovenian: V drugem, 26-tedenskem, randomiziranem, dvojno slepem preskušanju so preučevali prehod z zdravljenja z bazalnim insulinom na zdravilo Xultophy ali na insulin degludek pri bolnikih, ki niso bili zadostno urejeni z zdravljenjem z bazalnim insulinom (20-40 enot) in metforminom, samim ali v kombinaciji s sulfonilsečnino/glinidi.
English: Add on to metformin ± pioglitazone
Slovenian: Dodatek k metforminu ± pioglitazonu
English: When transferring from basal insulin therapy, the recommended starting dose of Xultophy is 16 dose steps (16 units insulin degludec and 0.6 mg liraglutide) (see section 4.4 and 5.1).
Slovenian: Priporočeni začetni odmerek zdravila Xultophy pri prehodu z zdravljenja z bazalnim insulinom je 16 odmernih korakov (16 enot insulina degludek in 0,6 mg liraglutida) (glejte poglavji 4.4 in 5.1).
English: Nausea, diarrhoea, vomiting, constipation, dyspepsia, gastritis, abdominal pain, gastroesophageal reflux disease, abdominal distension
Slovenian: dispepsija, gastritis, bolečina v trebuhu, gastroezofagealna refluksna bolezen,
English: Solution for injection Multipack: 10 (2 packs of 5) 3 mL pre-filled pens
Slovenian: raztopina za injiciranje Pakiranje po več enot: 10 napolnjenih injekcijskih peresnikov s 3 ml (2 pakiranji po 5).
English: The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia was 0.02 (2 patients out of 288) for Xultophy and 0.00 (0 patients out of 146) for placebo.
Slovenian: Delež hude hipoglikemije na bolnikov-let izpostavljenosti (odstotek bolnikov) je bil pri zdravilu Xultophy 0,02 (2 od 288 bolnikov), pri placebu pa 0,00 (0 od 146 bolnikov).
English: Xultophy is a medicine that contains insulin degludec and liraglutide.
Slovenian: Učinkovini zdravila Xultophy sta insulin degludek in liraglutid.
English: The dose counter shows the dose in dose steps.
Slovenian: Števec odmerka kaže odmerek v odmernih korakih.
English: Xultophy can be used in patients with mild or moderate hepatic impairment.
Slovenian: Zdravilo Xultophy se lahko uporablja pri bolnikih z blago do zmerno okvaro jeter.
English: How to use Xultophy
Slovenian: Kako uporabljati zdravilo Xultophy
English: The following serious side effects may happen with this medicine:
Slovenian: Pri uporabi tega zdravila se lahko pojavijo spodaj našteti resni neželeni učinki:
English: Xultophy is administered subcutaneously by injection in the thigh, the upper arm or the abdomen.
Slovenian: Zdravilo Xultophy se injicira subkutano v stegno, nadlaket ali trebušno steno.
English: IDegLira=Xultophy, IGlar=insulin glargine
Slovenian: IDegLira=zdravilo Xultophy, IGlar=insulin glargin
English: • The maximum daily dose of Xultophy is 50 dose steps (50 units of insulin degludec and 1.8 mg of liraglutide).
Slovenian: • Največji dnevni odmerek zdravila Xultophy je 50 odmernih korakov (50 enot insulina degludek in 1,8 mg liraglutida).
English: Octreotide and lanreotide - used for treatment of acromegaly (a rare illness with too much growth hormone).
Slovenian: Oktreotid in lanreotid (uporabljata se za zdravljenje akromegalije, redke hormonske motnje, ki je posledica čezmernega nastajanja rastnega hormona) lahko zvišata ali znižata koncentracijo krvnega sladkorja.
English: GLP-1 receptor agonist dose was to be continued unchanged from baseline
Slovenian: Odmerek agonista receptorjev GLP-1 je ostal nespremenjen od izhodišča
English: Xultophy is given once daily by subcutaneous administration.
Slovenian: Odmerjanje Zdravilo Xultophy se uporablja enkrat na dan v obliki subkutane injekcije.
English: • Belching (eructation) and wind (flatulence).
Slovenian: • glasno izpahovanje plinov iz želodca (riganje) in vetrovi (flatulenca)
English: In case of discontinuation of Xultophy, ensure that instruction for initiation of alternative antidiabetic treatment is followed.
Slovenian: V primeru prenehanja uporabe zdravila Xultophy je treba zagotoviti, da se bolniku uvede druga zdravila za zdravljenje sladkorne bolezni.
English: • Swelling of arms or legs (peripheral oedema) - when you first start using your medicine, your body may keep more water than it should.
Slovenian: • otekanje rok ali nog (periferni edem); po začetku uporabe zdravila lahko v telesu zastaja več vode, kot je normalno, kar povzroči otekanje gležnjev in drugih sklepov.
English: Add-on to oral glucose-lowering medicinal products Adding Xultophy to metformin alone or in combination with pioglitazone in a 26-week randomised, controlled, open-label trial resulted in 60.4% of patients treated with Xultophy reaching a target of HbA1c <7% without confirmed hypoglycaemic episodes after 26 weeks of treatment.
Slovenian: Xultophy dodali k metforminu ali h kombinaciji metformina in pioglitazona, je po 26 tednih zdravljenja ciljno vrednost HbA1c < 7 % brez potrjenih hipoglikemij doseglo 60,4 % bolnikov,
English: If you drink alcohol, your need for Xultophy may change.
Slovenian: S spremembo prehrane se lahko spremeni potreba po zdravilu Xultophy.
English: The signs may include bruising, bleeding, pain, redness, hives, swelling or itching - these usually go away after a few days.
Slovenian: • reakcije na mestu injiciranja (znaki lahko vključujejo modrice, krvavitve, bolečino, rdečino, koprivnico, oteklino ali srbenje); ti neželeni učinki običajno minejo v nekaj dneh.
English: Inform your doctor straight away if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).
Slovenian: Če opazite znake srčnega popuščanja, kot so neobičajno težko dihanje, hitro povečanje telesne mase ali lokalizirano otekanje (edem), o tem nemudoma obvestite svojega zdravnika.
English: IDegLira=Xultophy
Slovenian: IDegLir a= zdravilo Xultophy
English: The overall exposure of insulin degludec was equivalent following administration of Xultophy versus insulin degludec alone while the Cmax was higher by 12%.
Slovenian: Pri uporabi zdravila Xultophy je bila celokupna izpostavljenost insulinu degludek enaka kot pri uporabi insulina degludek samega, največja koncentracija (Cmax) pa je bila večja za 12 %.
English: There is no experience with Xultophy in children and adolescents under 18 years old.
Slovenian: Pri otrocih in mladostnikih, mlajših od 18 let, ni izkušenj z uporabo zdravila Xultophy.
English: If you do not check the flow, you may get too little medicine, or no medicine at all.
Slovenian: Če pretoka ne boste preverili, lahko injicirate premajhno količino zdravila ali celo nič, posledično pa se lahko koncentracija krvnega sladkorja zveča.
English: Non-clinical data reveal no special hazards for human based on conventional studies of safety pharmacology, repeat-dose toxicity, or genotoxicity.
Slovenian: Neklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih in genotoksičnosti ne kažejo posebnega tveganja za človeka.
English: The proportion was significantly larger than observed with insulin degludec (40.9%, odds ratio 2.28, p <0.0001) and similar to that observed with liraglutide (57.7%, odds ratio 1.13, p=0.3184).
Slovenian: (40,9 %, razmerje obetov 2,28, p<0,0001) in podoben deležu pri liraglutidu (57,7 %, razmerje obetov
English: • Measure your blood sugar if possible and rest. You may need to measure your blood sugar more than once.
Slovenian: • Če je mogoče, si izmerite koncentracijo krvnega sladkorja in počivajte.
English: Patients (%) achieving HbA1c <7% All patients
Slovenian: Bolniki (%), ki so dosegli vrednost HbA1c < 7 %
English: Usual warning symptoms (see section 4.8) of hypoglycaemia may disappear in patients with long-standing diabetes.
Slovenian: Pri bolnikih z dolgotrajno sladkorno boleznijo lahko običajni opozorilni simptomi hipoglikemije izginejo (glejte poglavje 4.8).
English: Always make sure that a drop appears at the needle tip before you inject.
Slovenian: Pred injiciranjem se vedno prepričajte, da se na konici igle pojavi kapljica.
English: It delivers doses from: - 1 dose step - to a maximum of 50 dose steps (50 units insulin degludec + 1.8 mg liraglutide)
Slovenian: - od 1 odmernega koraka - do največ 50 odmernih korakov (50 enot insulina degludek + 1,8 mg liraglutida).
English: If pancreatitis is suspected, Xultophy should be discontinued; if acute pancreatitis is confirmed, Xultophy should not be restarted.
Slovenian: Ko se potrdi nastanek akutnega pankreatitisa, se zdravljenja z zdravilom Xultophy ne sme več uvesti.
English: The dose counter on the pen shows the number of dose steps.
Slovenian: Števec odmerka na injekcijskem peresniku prikazuje število odmernih korakov.
English: Ethnic origin had no clinically relevant effect on the pharmacokinetics of Xultophy based on results from a population pharmacokinetic analysis including White, Black, Indian, Asian and Hispanic groups.
Slovenian: Rezultati analize populacijske farmakokinetike kažejo, da etnično poreklo, vključno z belci in črnci ter osebami indijskega, azijskega ali hispanskega porekla, nima klinično pomembnega vpliva na farmakokinetiko zdravila Xultophy.
English: The maximum daily dose of Xultophy is 50 dose steps (50 units insulin degludec and 1.8 mg liraglutide).
Slovenian: Največji dnevni odmerek zdravila Xultophy je 50 odmernih korakov (50 enot insulina degludek in 1,8 mg liraglutida).
English: Tabulated list of adverse reactions Adverse reactions associated with Xultophy are given below, listed by system organ class and frequency.
Slovenian: Neželeni učinki, povezani z uporabo zdravila Xultophy, so v nadaljevanju navedeni glede na organski sistem in pogostnost.
English: Xultophy is used with oral medicines for diabetes (such as metformin, pioglitazone and sulfonylurea medicines).
Slovenian: zdravila z metforminom, s pioglitazonom in sulfonilsečnino).
English: All cause death
Slovenian: MI brez smrtnega izida Smrt zaradi katerega koli vzroka
English: If your blood sugar gets low, see the advice in section 4 ‘Low blood sugar (hypoglycaemia)'.
Slovenian: Če se koncentracija krvnega sladkorja prekomerno zmanjša, glejte nasvete v poglavju 4, podpoglavju “Prenizek krvni sladkor (hipoglikemija)”.
English: • does not make enough insulin to control the level of sugar in your blood or
Slovenian: • da proizvede dovolj insulina za zadostno uravnavanje koncentracije krvnega sladkorja ali • da pravilno izkoristi v telesu nastali insulin.
English: Thyroid adverse events, such as goitre have been reported in clinical trials with GLP-1 receptor agonists including liraglutide, and in particular in patients with pre-existing thyroid disease.
Slovenian: V kliničnih preskušanjih agonistov receptorjev GLP-1, vključno z liraglutidom, so poročali o pojavu ščitničnih neželenih učinkov, kot je golšavost, in sicer še posebej pri bolnikih z že obstoječo boleznijo ščitnice.
English: Figure 2 Mean HbA1c (%) by treatment week in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or in combination with metformin
Slovenian: Slika 2: Povprečna vrednost HbA1c (%) po tednih zdravljenja pri bolnikih z nezadostno urejeno sladkorno boleznijo tipa 2 pri zdravljenju s sulfonilsečnino, samo ali v kombinaciji z metforminom
English: Atorvastatin Cmax was decreased by 38% and median tmax was delayed from 1 h to 3 h with liraglutide.
Slovenian: atorvastatina zmanjšala za 38 %, mediani čas do največje koncentracije (tmax) pa z 1 ure podaljšal na 3 ure.
English: No studies have been performed with Xultophy in children and adolescents below 18 years of age.
Slovenian: Pri otrocih in mladostnikih, mlajših od 18 let, študij z zdravilom Xultophy niso izvedli.
English: Headache, slurred speech, fast heartbeat, cold sweat, cool pale skin, feeling sick (nausea), feeling very hungry, shaking, feeling nervous or worried, unusually tired, weak and sleepy or confused, difficulty concentrating, short-lasting changes in your sight.
Slovenian: Opozorilni znaki prenizkega krvnega sladkorja - lahko se pojavijo nenadoma Glavobol, nerazločno govorjenje, hitro bitje srca, hladno znojenje, hladna in bleda koža, siljenje na bruhanje, huda lakota, tresenje, živčnost ali zaskrbljenost, nenavadna utrujenost, oslabelost in zaspanost ali zmedenost, težave s koncentracijo, kratkotrajne motnje vida.
English: • Severe hypoglycaemic episodes, where the patient is not able to treat himself, can be treated with glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person, or with glucose given intravenously by a healthcare professional.
Slovenian: • Hude hipoglikemije, ko bolnik ne more ukrepati sam, se lahko zdravi z glukagonom (0,5 do
English: In vitro data suggest that the potential for pharmacokinetic drug interactions related to CYP interaction and protein binding is low for both liraglutide and insulin degludec.
Slovenian: Farmakokinetične interakcije In vitro podatki kažejo, da je potencial liraglutida in insulina degludek za farmakokinetične interakcije,
English: This may lead to high blood sugar level.
Slovenian: Ukrepanje v primeru previsokega krvnega sladkorja
English: The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia was 0.01 (1 patient out of 291) for Xultophy and 0.00 (0 patients out of 199) for GLP-1 receptor agonists.
Slovenian: Delež hude hipoglikemije na bolnikov-let izpostavljenosti (odstotek bolnikov) je bil pri zdravilu Xultophy 0,01 (1 od 291 bolnikov), pri agonistih receptorjev GLP-1 pa 0,00 (0 od 199 bolnikov).
English: Store in a refrigerator
Slovenian: POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte v hladilniku.
English: Inflammatory bowel disease and diabetic gastroparesis There is no experience with Xultophy in patients with inflammatory bowel disease and diabetic gastroparesis.
Slovenian: Vnetna črevesna bolezen in diabetična gastropareza Pri bolnikih s kronično vnetno črevesno boleznijo in z diabetično gastroparezo ni izkušenj z uporabo zdravila Xultophy, zato uporaba zdravila Xultophy pri teh bolnikih ni priporočljiva.
English: Therapy with GLP-1 receptor agonists should be discontinued prior to initiation of Xultophy.
Slovenian: Prehod z zdravljenja z agonistom receptorjev GLP-1 Pred uvedbo zdravljenja z zdravilom Xultophy je treba zdravljenje z agonistom receptorjev GLP-1
English: High blood sugar may happen if you:
Slovenian: Previsok krvni sladkor se lahko pojavi, če:
English: Component of a multipack, can't be sold separately
Slovenian: Ni za ločeno prodajo.
English: In all trials, the starting dose was given according to label and a twice-weekly titration regimen for Xultophy was used (see Table 2).
Slovenian: Xultophy je bila uporabljena shema titriranja dvakrat na teden (glejte preglednico 2).